Ipsos Launches HS Therapy Monitor

Ipsos Healthcare has launched its Hidradenitis Suppurativa (HS) Therapy Monitor in Europe's big five markets (Germany, the UK, France, Italy and Spain), with plans to extend to additional markets at a later date.

The new HS Monitor, which is part of Ipsos' Autoimmune Real World Evidence (RWE) portfolio, provides a syndicated study looking at actual evidence on the treatment of HS patients. Subscribers will be able to examine the size of the HS market in each country (including the biologic market), understand HS patient journeys, gauge doctors' perceptions of products used to treat HS, and assess their treatment approaches.

The HS Therapy Monitor extends Ipsos' Autoimmune RWE portfolio, which also includes Rheumatoid Arthritis, Spondyloarthropathies, Lupus, Crohn's Disease, Ulcerative Colitis, Psoriasis and Multiple Sclerosis diseases. Commenting on the latest launch, Paul O'Meara (pictured), SVP of Autoimmune Therapy Monitors, said: 'New biological treatments - together with their biosimilar counterparts - are transforming the autoimmune market, offering greater treatment options for patients and disrupting the traditional treatment paradigm. The ongoing expansion of Ipsos' Autoimmune Therapy Monitor portfolio to include Hidradenitis Suppurativa will enable our clients, both local and global, to keep track of these therapeutic areas during this exciting time'.

Web site: www.ipsos.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.